Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. April 2018 08:00 ET | Quelle: Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals Provides Corporate Update and Reports First Quarter Financial and Operational Results

Presented inarigivir 25 mg and 50mg cohorts from Phase 2 ACHIEVE trial in chronic hepatitis B patients at two scientific conferences Continues to advance SB 11285, a next-generation STING agonist,...
10. April 2018 08:30 ET | Quelle: Spring Bank Pharmaceuticals, Inc.

Spring Bank Announces Expanded Inarigivir Data from the ACHIEVE Trial to Be Presented at The International Liver Congress™

*Results from full 24 weeks of dosing from the first two cohorts of Part A in the ongoing Phase 2 ACHIEVE trial in hepatitis B to be highlighted in oral and poster presentations *30% of patients in...
14. März 2018 08:00 ET | Quelle: Spring Bank Pharmaceuticals, Inc.

Spring Bank Announces Presentation of Combined Inarigivir 25 mg and 50 mg 12 and 24 Week ACHIEVE Results Demonstrating Enhanced Anti-Viral Efficacy in HBeAg-Negative Patients

Data from the combined first two low dose inarigivir cohorts at weeks 12 and 24 with sequential Viread dosing demonstrate significant reductions in HBV DNA, HBV RNA and HBsAg Data to be presented at...
09. März 2018 14:19 ET | Quelle: Spring Bank Pharmaceuticals, Inc.

Spring Bank to Present at Cowen & Company 38th Annual Health Care Conference

HOPKINTON, Mass., March 09, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
05. März 2018 16:01 ET | Quelle: Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals Appoints Timothy Clackson, Ph.D., to its Board of Directors

Spring Bank strengthens Board of Directors with the addition of aprominent biopharma R&D veteran HOPKINTON, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc....
20. Februar 2018 16:30 ET | Quelle: Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial and Operational Results

2017 highlighted by continued progress with global inarigivir clinical program for the treatment of chronic HBV and advancement of next-generation STING agonist candidate, SB 11285, towards the clinic...
12. Februar 2018 08:00 ET | Quelle: Spring Bank Pharmaceuticals, Inc.

Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2017 Results on Wednesday, February 21

Conference Call to be Held at 8:30am Eastern Time HOPKINTON, Mass., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company...
09. Januar 2018 08:30 ET | Quelle: Spring Bank Pharmaceuticals, Inc.

Spring Bank Strengthens Management Team to Enhance Operations

Appoints Kevin Leach, Ph.D., as Vice President, Nonclinical & Translational Research Promotes Garrett Winslow to General Counsel HOPKINTON, Mass., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Spring Bank...
15. November 2017 16:30 ET | Quelle: Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE Trial

Low Dose of Inarigivir Soproxil (50mg) Monotherapy Demonstrates a Favorable Safety Profile and Significant Dose-Dependent Antiviral Activity, Meeting Both Primary Endpoints Conference Call Scheduled...
07. November 2017 08:00 ET | Quelle: Spring Bank Pharmaceuticals, Inc.

Spring Bank to Present at Piper Jaffray’s 29th Annual Healthcare Conference

HOPKINTON, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

Vorherige Seite